Medicare Enrolled

Dr. Mohammad Ursani, M.D.

Rheumatology · Conroe, TX
Practice pattern: Mixed Practice— Diverse clinical practice across multiple procedure types
Consulting-driven
17450 ST LUKES WAY STE 250, Conroe, TX 77384
3462302442
In practice since 2014 (12 years)
NPI: 1083031421 verify on NPPES ↗
Very High
DATA COVERAGE
Data in 4 of 4 federal sources
Measures public federal data availability — not provider quality
Informational, not a quality rating. This page presents federal public records about Dr. Ursani from CMS (NPPES, Open Payments, Medicare Provider Utilization, PECOS). It is not medical advice, an endorsement, or a judgment of clinical quality. Always consult the provider directly and a licensed clinician for medical decisions. Read methodology →
Are you Dr. Ursani? Request a correction or review of any data shown here. Provider portal →

What this data tells you about Dr. Ursani

Dr. Mohammad Ursani is a rheumatology in Conroe, TX, with 12 years in practice. Based on federal Medicare data, Dr. Ursani performed 24,990 Medicare services across 701 unique beneficiaries.

Between the years covered by Open Payments, Dr. Ursani received a total of $37,091 from 54 pharmaceutical and/or device companies across 533 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common in rheumatology. The majority of payments are for consulting, which typically reflects recognized clinical expertise sought by manufacturers. Patients may wish to discuss these relationships with their provider.

The Data Coverage level for Dr. Ursani is Very High — reflecting how much public federal data is available about this provider. This is not a quality rating. Patients are encouraged to use this data as one of several factors when choosing a healthcare provider.

✓ 12 years in practice▲ Top 31% volume in TX$ $37,091 industry payments

Medicare Practice Summary

Medicare Utilization ↗
24,990
Medicare services
Top 31% in TX for rheumatology
701
Unique beneficiaries
$14
Avg. Medicare payment
Medicare patients only (65+ / disabled) · Not a quality rating · How to read this →
~2,082 Medicare services per year of practice

Top procedures by volume

Ranked by number of services performed for Medicare patients. Avg. submitted charge is what the provider billed; avg. Medicare payment is what CMS paid.

ProcedureVolumeAvg. paidAvg. submitted
Golimumab infusion (Simponi Aria)19,923$10$40
Denosumab injection (Prolia/Xgeva)3,540$18$55
Office visit, established patient (30-39 min)373$92$347
Administration of chemotherapy into vein, 1 hour or less202$101$377
Infusion into a vein for therapy, prevention, or diagnosis, additional sequential infusion, 1 hour or less150$23$82
Administration of chemotherapy into vein, each additional hour131$23$80
Injection, diphenhydramine hcl, up to 50 mg128$1$3
Infusion into a vein for therapy, prevention, or diagnosis, 1 hour or less115$50$180
Office visit, established patient (20-29 min)115$65$244
Injection, methylprednisolone sodium succinate, up to 40 mg90$3$11
Drug injection, under skin or into muscle71$11$39
Injection of additional new drug or substance into vein51$12$44
New patient office visit (45-59 min)35$126$452
Joint injection, major joint24$46$174
New patient office visit (30-44 min)21$87$304
Office visit, established patient, complex (40-54 min)21$135$484
How to read this data: This reflects Medicare patients only (typically 65+). Payment amounts are what Medicare paid the provider, not your out-of-pocket cost. A higher procedure volume generally indicates more experience with that procedure.
80.8% high complexity
17.0% medium
2.3% routine

Industry Payment Transparency

Open Payments through 2024 ↗
$37,091
Total received (2018-2024)
Avg $5,299/year across 7 years
Top 13% in TX for rheumatology
54
Companies
533
Individual payments
All payments are legal and publicly reported · Not evidence of wrongdoing · How to interpret →

Payment profile

Industry payments classified by relationship type. Not all payments are equal — research and consulting reflect different relationships than speaking programs or meals.

Consulting
Expert advisory fees, typically reflecting recognized clinical expertise
$28,688 (77.3%)
Meals & Travel
Food, beverages, travel, and lodging — typically low-value
$8,285 (22.3%)
Speaking / Promotional
Speaker programs, honoraria, and industry-sponsored educational events
$118 (0.3%)

Payment trend by year

Annual totals from pharmaceutical and medical device companies.

2024
$9,623
2023
$14,438
2022
$4,826
2021
$4,997
2020
$497
2019
$1,358
2018
$1,352

Payments by company (2024)

Consulting
Speaking
Meals & Travel
Research
UCB, Inc.
$16,524
Novartis Pharmaceuticals Corporation
$5,265
NOVARTIS PHARMACEUTICALS CORPORATION
$4,750
Janssen Biotech, Inc.
$3,427
Amgen Inc.
$1,780
ABBVIE INC.
$935
Genentech USA, Inc.
$590
GlaxoSmithKline, LLC.
$418
AstraZeneca Pharmaceuticals LP
$368
PFIZER INC.
$345
AbbVie Inc.
$284
Lilly USA, LLC
$274
Celgene Corporation
$178
Organon LLC
$178
Horizon Therapeutics plc
$165
Johnson & Johnson Health Care Systems Inc.
$129
Boehringer Ingelheim Pharmaceuticals, Inc.
$109
Mallinckrodt Hospital Products Inc.
$93
Aurinia Pharma U.S., Inc.
$92
Radius Health, Inc.
$81
Fresenius Kabi USA, LLC
$71
Octapharma USA, Inc.
$67
Ipsen Biopharmaceuticals, Inc
$57
ARRAY BIOPHARMA INC
$56
Merck Sharp & Dohme LLC
$53
Takeda Pharmaceuticals U.S.A., Inc.
$49
Organon Llc
$47
Alexion Pharmaceuticals, Inc.
$45
Biocompatibles, Inc.
$43
Tempus AI, Inc
$41
TerSera Therapeutics LLC
$38
Seagen Inc.
$38
Otsuka America Pharmaceutical, Inc.
$38
Incyte Corporation
$38
Mallinckrodt LLC
$35
Dova Pharmaceuticals
$35
Mallinckrodt Enterprises LLC
$35
Agios Pharmaceuticals, Inc.
$34
GENZYME CORPORATION
$27
Antares Pharma, Inc.
$26
ANI Pharmaceuticals, Inc.
$25
Eisai Inc.
$21
Puma Biotechnology, Inc.
$20
Teva Pharmaceuticals USA, Inc.
$19
Acceleron Pharma, Inc.
$18
Sandoz Inc.
$18
Clovis Oncology, Inc.
$17
Mylan Institutional Inc.
$16
Horizon Pharma plc
$16
Janssen Pharmaceuticals, Inc
$14
Rigel Pharmaceuticals, Inc.
$14
Pharmacyclics LLC, An AbbVie Company
$13
Hikma Pharmaceuticals USA
$11
Merck Sharp & Dohme Corporation
$11
Top 3 companies account for 71.6% of total payments
Associated products mentioned in payments ›
ACTHAR · ADAKVEO · ADCETRIS · AFINITOR · Actemra · BENLYSTA · BRAFTOVI · Bimzelx · CALQUENCE · COSENTYX · CYLTEZO · Cimzia · Doptelet · EVENITY · Enbrel · HADLIMA · HUMIRA · HYRIMOZ · Hulio · IDACIO · ILARIS · IMBRUVICA · INFLECTRA · Imbruvica · Inrebic · JAKAFI · KANJINTI · KEVZARA · KEYTRUDA · KRYSTEXXA · LUPKYNIS · Lenvima · MEKINIST · Mitigare · NEXPLANON · NINLARO · NUCALA · OCTAGAM IMMUNE GLOBULIN (HUMAN) · OFEV · Otezla · Otrexup · PADCEV · PURIFIED CORTROPHIN GEL · PYRUKYND · Prolia · Quzyttir · RAYOS · REMICADE · RENFLEXIS · RINVOQ · Reblozyl · Revlimid · Rituxan · Rubraca · SAPHNELO · SIMPONI · SIMPONI ARIA · SKYRIZI · SOMATULINE DEPOT · SPRYCEL · STELARA · STRENSIQ · TALTZ · TAVNEOS · THERASPHERE - BIO · THERASPHERE-BIO · TIBSOVO · TREMFYA · Tavalisse · Tavneos · Truxima · Tymlos · XARELTO · XELJANZ · XGEVA · XT CDX
Should you be concerned? Payments from pharmaceutical and device companies are legal and common — 57% of U.S. physicians receive at least one. They often reflect legitimate consulting, research, or education. What matters is whether a recommended drug or device appears in your doctor's payment records. If so, consider asking your doctor about it. How to interpret this data →

The majority of payments (77%) are consulting fees, which typically reflect recognized clinical expertise sought by manufacturers.

Equivalent to $148 per 100 Medicare services performed
Looking for a rheumatology in Conroe?
Compare rheumatologys in the Conroe area by procedure volume, costs, and industry payment transparency.
Browse rheumatologys nearby

Geographic Context

Rheumatologys within 10 mi
28
Per 100K population
4.3
County median income
$97,266
Nearest hospital
ST LUKE'S THE WOODLANDS HOSPITAL
0.0 mi

Data Sources

Provider Registry NPPESWeekly updates
Medicare Enrollment PECOSMonthly updates
Practice Data Medicare Util.Annual (CY lag)
Industry Payments Open PaymentsCY 2024
Disciplinary History— Not publicN/A

This provider has data in 4 of 4 available federal datasets, with a Data Coverage level of Very High. This measures how much public data is available about a provider — not how good they are. How we calculate this →

Summary

Dr. Ursani is a mixed practice specialist, with moderate Medicare volume, and high industry engagement (consulting-driven, top 13%).

This summary is auto-generated from federal data. It describes data availability and patterns — not clinical quality. Read our methodology →

Frequently Asked Questions

Is Dr. Ursani experienced with golimumab infusion (simponi aria)?
Based on Medicare claims data, Dr. Ursani performed 19,923 golimumab infusion (simponi aria) services. Research suggests that higher procedure volume is often associated with better outcomes, particularly for complex procedures. Note that Medicare data only captures patients aged 65 and older, so the total practice volume across all patients is likely higher.
Does Dr. Ursani receive payments from pharmaceutical companies?
Yes. Dr. Ursani received a total of $37,091 from 54 companies across 533 individual payments. These payments are legal, publicly disclosed under the federal Sunshine Act, and common among physicians — 57% of all U.S. physicians receive at least one industry payment. Patients may wish to ask their doctor about these relationships, especially if a recommended drug or device appears in the payment records.
How do Dr. Ursani's costs compare to other rheumatologys in Conroe?
Dr. Ursani's average Medicare payment per service is $14. Note that these figures represent what Medicare pays, not your out-of-pocket cost, which depends on your specific insurance plan and deductible. Procedure-level data above shows both what was submitted and what Medicare paid for each service type.
What does Data Coverage mean?
Data Coverage (currently Very High for Dr. Ursani) measures how much public federal data is available about a provider. It is not a quality rating. A "Very High" or "High" level means the provider has data across multiple federal sources (NPPES, PECOS, Medicare Utilization, Open Payments), indicating a long track record of practice, Medicare participation, and industry disclosure. A "Low" or "Moderate" level may simply mean the provider is newer, does not see Medicare patients, or has not received any industry payments — none of which are inherently negative. Read our full methodology →
Is this data up to date?
Each data source has its own update cycle. Provider registry data (NPPES) is updated weekly. Medicare enrollment (PECOS) is updated monthly. Medicare practice data has a ~2 year lag — the most recent available is typically 2 years prior. Industry payment data (Open Payments) is published annually, usually in June, covering the prior calendar year. We display the data date prominently on each section so you always know how current it is. See our data freshness policy →
About this page

All data on this page is sourced verbatim from public federal records published by the U.S. Centers for Medicare & Medicaid Services (CMS): NPPES ↗, Open Payments ↗, Medicare Provider Utilization ↗, and PECOS. Publication is mandated by the Physician Payments Sunshine Act (§6002 ACA, 42 U.S.C. §1320a-7h) and the Freedom of Information Act.

This page is not medical advice, an endorsement, a recommendation, or a quality rating. The Transparency Score measures data completeness — how much federal information exists for this provider — not clinical performance, patient outcomes, or quality of care. Always verify information directly with the provider and consult a licensed clinician before making medical decisions.

Provider corrections: Provider portal · Privacy questions: Privacy Policy · Terms: Terms of Use · Methodology: Methodology

Data Disclaimer — Data sourced from the Centers for Medicare & Medicaid Services (CMS): National Plan and Provider Enumeration System (NPPES), Open Payments program, Medicare Provider Utilization and Payment Data, and Provider Enrollment & Certification data (PECOS). Published under the Freedom of Information Act (FOIA). This website is not affiliated with, endorsed by, or authorized by CMS, HHS, or the U.S. Government. Data may contain errors as reported to CMS by providers and reporting entities. Payments from industry are legal and do not indicate wrongdoing. Medicare data reflects only patients aged 65+ or those with qualifying disabilities. For corrections, contact CMS directly. This information does not constitute medical advice and should not be used as the sole basis for choosing a healthcare provider. Procedure descriptions use plain language and do not reference CPT® codes, which are copyrighted by the American Medical Association. Full methodology → · Report a data error → · Privacy policy →